Novartis | NOVN - Cost Of Sales

Stock Price
115.60
Daily Change
-1.28 -1.10%
Monthly
-9.67%
Yearly
16.50%
Q1 Forecast
118.31

Novartis reported $3.54B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alcon AG USD 1.2B 46M Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Autolus Therapeutics Ltd USD 28.64M 3.73M Sep/2025
Bayer EUR 4.5B 194M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Fresenius EUR 4.45B 262M Dec/2025
Fresenius Medical Care EUR 3.68B 38.37M Dec/2025
Galapagos EUR 455K 84.28M Dec/2025
Genmab DKK 81M 23M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
GRIFOLS EUR 1.29B 163.12M Dec/2025
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
J&J USD 7.97B 689M Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.29B 183M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Novartis USD 3.54B 7M Dec/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Orion EUR 186.6M 17.6M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Philips EUR 2.81B 417M Dec/2025
Recordati EUR 199.91M 20.12M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
UCB EUR 1.07B 146M Dec/2025